Physician profile
Yiding Li
NPI 1295939494
$7,958.24
in general payments reported to CMS, 2019-2025
25 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,242 · 2020: $89.46 · 2021: $814 · 2022: $705 · 2023: $420 · 2024: $1,100 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,962.89 | 2019-2024 | Vemlidy |
| Amgen INC. | $1,388.98 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $483.79 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $409.55 | 2019-2025 | |
| Lilly USA, LLC | $303.60 | 2022-2024 | Jardiance |
| Esperion Therapeutics, INC. | $276.41 | 2021-2022 | |
| Angiodynamics, INC. | $260.48 | 2024 | Angiodynamics, Nanoknife |
| Novo Nordisk INC | $226.57 | 2019 | |
| Amarin Pharma, INC. | $189.28 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $156.48 | 2020-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.27 | 2022-2023 | Jardiance |
| Insmed, INC. | $138.89 | 2019 | |
| Abbott Laboratories | $136.15 | 2022 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Boston Scientific Corporation | $125.00 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $120.17 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Medtronic, INC. | $98.15 | 2025 | Closurefast |
| Nuvasive, INC. | $90.90 | 2022 | |
| Exact Sciences Corporation | $65.98 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $42.85 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $40.22 | 2025 | Zoryve |
| Ibsa Pharma INC. | $18.33 | 2021 | |
| Genentech USA, INC. | $15.13 | 2021 | |
| Allergan, INC. | $14.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiding Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.